Download PDF
Thromb Haemost 1964; 11(01): 038-050
DOI: 10.1055/s-0038-1654804
Originalarbeiten — Original Articles — Travaux Originaux
Schattauer GmbH

Further Studies on the Effect of Dextran of Various Molecular Weight on the Coagulation Mechanism

Inga Marie Nilsson
1   Department of Medicine, University of Lund, Allmänna Sjukhuset, Malmö; Department of Surgery, University of Lund, Allmänna Sjukhuset, Malmö, Sweden
,
Oddvar Eiken
1   Department of Medicine, University of Lund, Allmänna Sjukhuset, Malmö; Department of Surgery, University of Lund, Allmänna Sjukhuset, Malmö, Sweden
› Author AffiliationsThis work was supported by grants from the Swedish Medical Research Council and from AB Pharmacia, Uppsala, Sweden.
Further Information

Publication History

Publication Date:
24 July 2018 (online)

    Permissions and Reprints

Summary

Dextran fractions of different molecular weights were given to dogs in order to ascertain at which molecular weight dextran interferes with the coagulation factors.

1. Infusions of dextran with an average molecular weight of 130,000 (Intradex®) and in doses of 1.5 g dextran per kg body weight induced a moderate coagulation defect. There was a slight prolongation of the bleeding time and a slight drop in platelet count. Values for AHF, factor V, prothrombin and factor VII, and fibrinogen declined by 10 to 40% of the original values.

2. Infusions of dextran with an average molecular weight of 75,000 (Macrodex®) in doses of 1.5 g per kg body weight did not produce any significant changes in bleeding time and platelet count. The AHF level decreased by 40% and the levels of prothrombin and factor VII, factor V and fibrinogen by about 10% of the original values. In a dose of 2 g per kg body weight this fraction produced a significant coagulation defect with a fall of the various coagulation factors by about 40 to 50%.

3. A dextran fraction with an average molecular weight of 60,000 in doses of 1.5 g per kg body weight did not prolong the bleeding time and caused only a very slight decrease in platelet count. There were no changes in the values for AHF, factor V, prothrombin and factor VII but a slight drop occurred in the fibrinogen levels.

4. Dextran with an average molecualr weight of 40,000 (Rheomacrodex ® ) in doses of 1.5 g per kg body weight did not affect the bleeding time or the platelet count. Nor did any significant decline occur in the amounts of the other coagulation factors.

No changes in the Duke or in the Ivy bleeding times were observed in human beings given Macrodex® and Rheomacrodex® in doses of 1 g per kg body weight.

Intradex® and Macrodex® in doses of up to 1-1.5 g per kg bodyweight to persons with normal blood coagulation are considered not associated with any appreciable risk of haemorrhage, but they are contraindicated in patients with haemorrhagic diathesis. The experiments indicate that Rheomacrodex® in similar doses does not incur any risk of haemorrhage.

 

  • References

  • 1 Adant M. Quelques effects de l’injection intraveineuse de dextran et de polyvinylpyrrolidone au chien normal ou hépatectomisé. Bull. Acad. roy. Méd. Belg. 19: 264 1954;
    PubMedGoogle Scholar
  • 2 Adelson E. Bleeding time prolongation after dextran infusion. Bibl. haemat. (Basel) 07: 275 1958;
    PubMedGoogle Scholar
  • 3 Adelson E, Crosby W. H, Boeder W. H. Further studies of a hemostatic defect caused by intravenous dextran. J. Lab. clin. Med. 45: 441 1955;
    PubMedGoogle Scholar
  • 4 Bergentz S. E, Eiken O, Nilsson I. M. The effect of dextran of various molecular weight on the coagulation in dogs. Thrombos. Diathes. haemorrh. (Stuttg) 06: 15 1961;
    PubMedGoogle Scholar
  • 5 Bergentz S. E, Nilsson I. M. Effect of trauma on coagulation and fibrinolysis in dogs. Acta chir. scand. 122: 21 1961;
    PubMedGoogle Scholar
  • 6 Biörck G, Johansson B. W, Nilsson I. M. Blood coagulation studies in hedgehogs, in a hibernating and a non-hibernating state, and in dogs, hypothermic and normothermic. Acta physiol, scand. 56: 334 1962;
    CrossrefPubMedGoogle Scholar
  • 7 Blombäck B, Gardell S, Löfström B, Zetterqvist E. Effekt av operationstrauma och infusion av olika dextranfraktioner pâ blödningsoch koagulationsfaktorer. Nord. Med. 69: 155 1963;
    PubMedGoogle Scholar
  • 8 Bronwell A. W, Artz C. P, Sako Y. Evaluation of blood loss from a standardized wound after dextran. Surg. Forum. 05: 809 1954;
    PubMedGoogle Scholar
  • 9 Bryce D. M. Factors influencing the activity of thrombin preparations. J. Pharm. Pharmacol. 06: 451 1954;
    CrossrefPubMedGoogle Scholar
  • 10 Burstein M. Substances fibrinoplastiques et antifibrinoplastiques. Rev. Hémat. 07: 586 1952;
    PubMedGoogle Scholar
  • 11 Carbone J. V, Furth F. W, Scott Jr. R, Crosby W. H. An haemostatic defect associated with dextran infusion. Proc. Soc. exp. Biol. (N. Y) 85: 101 1954;
    CrossrefPubMedGoogle Scholar
  • 12 Fletcher F, Martin L. E, Racliffe A. H. Interaction of macromolecules and fibrinogen. Nature 170: 319 1952;
    PubMedGoogle Scholar
  • 13 Gelin L-E, Korsan-Bengtsen K, Ygge J, Zederfeldt B. Influence of low viscous dextran on the hemostatic mechanism. Acta chir. scand. 122: 324 1961;
    PubMedGoogle Scholar
  • 14 Godal H. C. The interaction of protamine with human fibrinogen and the significance of this interaction for the coagulation of fibrinogen. Scand. J. clin. Lab. Invest. 12: 433 1960;
    CrossrefPubMedGoogle Scholar
  • 15 Howard J. M, Teng C. T, Loeffler R. K. Studies of dextrans of various molecular sizes. Ann. Surg. 143: 369 1956;
    CrossrefPubMedGoogle Scholar
  • 16 Jacobaeus U. The effect of dextran on the coagulation of blood. Acta med. scand. 06: 505 1955;
    PubMedGoogle Scholar
  • 17 Jacobaeus U. Studies on the effect of dextran on the coagulation of blood. Acta med. scand., Suppl.. 157. 1957
    PubMedGoogle Scholar
  • 18 Jaenike J, Waterhouse C. Metabolic and hemodynamic changes induced by the prolonged administration of dextran. Circulation 11: 1 1955;
    CrossrefPubMedGoogle Scholar
  • 19 Langdell R. D, Adelson E, Furth F. W, Crosby W. H. Dextran and prolonged bleeding time. J. Amer. med. Ass. 166: 346 1958;
    CrossrefPubMedGoogle Scholar
  • 20 Laurell A. B. Influence of dextran on the conversion of fibrinogen to fibrin. Scand. J. clin. Lab. Invest. 03: 262 1951;
    CrossrefPubMedGoogle Scholar
  • 21 Long D, Sanches L, Varco R, Lillehei C. W. The use of low molecular weight dextran and serum albumin as plasma expanders in extracorporeal circulation. Surgery 50: 12 1961;
    PubMedGoogle Scholar
  • 22 Nilsson I. M, Blombäck M, Ramgren O. Haemophilia in Sweden. I. Coagulation studies. Acta med. scand. 170: 665 1961;
    PubMedGoogle Scholar
  • 23 Nilsson I. M, Magnusson S, Borchgrevink C. F. The Duke and Ivy methods for determination of the bleeding time. Thrombos. Diathes. haemorrh. (Stuttg) 10: 223 1963;
    PubMedGoogle Scholar
  • 24 Nilsson I. M, Olow B. Determination of fibrinogen and fibrinogenolytic activity. Thrombos. Diathes. haemorrh. (Stuttg) 08: 297 1962;
    PubMedGoogle Scholar
  • 25 Nilsson I. M, Olow B. Fibrinolysis induced by streptokinase in man. Acta chir. scand. 123: 247 1962;
    PubMedGoogle Scholar
  • 26 Raison JCA. A clinical report of the use of low-molecular-weight dextran in a rotating oxygenator. Thorax 17: 338 1962;
    CrossrefPubMedGoogle Scholar
  • 27 Scott J. S. Blood coagulation failure in obstetrics. Brit. med. J. II: 290 1955;
    PubMedGoogle Scholar
  • 28 Seegers W. H, Smith H. P. Factors which influence the activity of purified thrombin. Amer. J. Physiol. 137: 348 1942;
    PubMedGoogle Scholar
  • 29 Semple R. The effects of single large infusions of various dextran solutions on hypovolemic dogs. Canad. J. Biochem. 32: 670 1954;
    PubMedGoogle Scholar
  • 30 Semple R. Changes in protein fractions of dog plasma after bleeding and dextran infusion. J. Lab. clin. Med. 45: 61 1955;
    PubMedGoogle Scholar
  • 31 Swank R. Suspension stability of the blood after injections of dextran. J. appl. Physiol. 12: 125 1958;
    CrossrefPubMedGoogle Scholar